Protein Kinase Inhibitors: all 15,766 studies that test it

Page 6 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone LesionsRecruitingNCT07371182Not applicable
• Golidocitinib Combined With Selinexor for CAEBVDRecruitingNCT07369739Phase 2/3
• To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerRecruitingNCT07368998Phase 2
• Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix CancerNot yet recruitingNCT07368985Phase 2
• Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic MalignanciesRecruitingNCT07366801Phase 2/3
• Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)Not yet recruitingNCT07362836Phase 3
• A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsRecruitingNCT07361562Phase 1
• A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell TransplantRecruitingNCT07359859Phase 2
• A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or RearrangementRecruitingNCT07359820Phase 2
• A Study Comparing the MAGICTouch™ Sirolimus-coated Balloon With a Paclitaxel-coated Balloon for Treating Severe Narrowing or Blockage in the Femoropopliteal Arteries.Not yet recruitingNCT07359807Phase 2/3
• A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung CancerRecruitingNCT07358676Phase 2
• Baricitinib Effects on Procoagulant State in Rheumatoid ArthritisNot yet recruitingNCT07357649Phase 4
• Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRDNot yet recruitingNCT07357532Phase 2
• Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaRecruitingNCT07356245Phase 2
• Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone LymphomaRecruitingNCT07355699Phase 4
• A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian CancerNot yet recruitingNCT07355010Phase 2
• Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruitingNCT07354074Phase 2
• Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)RecruitingNCT07354061Phase 1/2
• FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT07353827Phase 2
• Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric CancerRecruitingNCT07353684Phase 2
• Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingNCT07352566Phase 4
• A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSLRecruitingNCT07350850Phase 2
• Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal MetastasisRecruitingNCT07348965Not applicable
• A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic ImpairmentRecruitingNCT07343960Phase 1
• The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic RosaceaRecruitingNCT07343635Not applicable
• Dasatinib for HIV-1 Reservoir ReductionRecruitingNCT07342491Phase 1
• ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLRecruitingNCT07342478Phase 3
• Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell TherapyRecruitingNCT07341191Phase 2
• Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )RecruitingNCT07340723Phase 2
• Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast CancerRecruitingNCT07340398Phase 2
• Prospective Single-Arm Clinical Trial of GO Regimen for HLH.RecruitingNCT07339345Phase 2/3
• Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR MutationsRecruitingNCT07336732Phase 2
• A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen SclerosusRecruitingNCT07335588Phase 3
• A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic SclerosisNot yet recruitingNCT07335562Phase 3
• ctDNA in HER2+ EBC Neoadjuvant TreatmentRecruitingNCT07335081Phase 2
• A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCCRecruitingNCT07334483Phase 2
• A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine TherapyRecruitingNCT07330544Phase 2
• Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk FactorsNot yet recruitingNCT07330076Phase 2
• Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingNCT07329322Phase 2
• Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or MutationsNot yet recruitingNCT07328919Phase 3
• Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIRecruitingNCT07326566Phase 2
• Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerRecruitingNCT07323641Phase 2
• Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.Not yet recruitingNCT07320963Phase 1/2
• ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingNCT07318389Early Phase 1
• Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerRecruitingNCT07318324Phase 1
• Optimal Dose of Zanubrutinib to Treat Adult Immune ThrombocytopeniaNot yet recruitingNCT07315373Phase 1
• Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerRecruitingNCT07315113Phase 1
• FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07314372Phase 2
• Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary AdenocarcinomaRecruitingNCT07314216Phase 2
• Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric CancerNot yet recruitingNCT07314203Phase 3
• Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune IntoleranceNot yet recruitingNCT07313202Phase 2
• Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic LeukemiaRecruitingNCT07311746Phase 1/2
• SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy FailureRecruitingNCT07311408Phase 2
• A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.Not yet recruitingNCT07307443Phase 2
• Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesRecruitingNCT07304739Phase 2
• Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung CancerNot yet recruitingNCT07303881Phase 2
• BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia PatientsNot yet recruitingNCT07301138Phase 2
• Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaRecruitingNCT07300514Phase 3
• Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular LymphomaRecruitingNCT07299149Phase 2
• A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisRecruitingNCT07299019Phase 3
• Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mgNot yet recruitingNCT07298148Phase 2
• Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALLRecruitingNCT07297914Phase 2/3
• First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative TreatmentNot yet recruitingNCT07297654Phase 2
• Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic AnemiaNot yet recruitingNCT07297550Phase 1/2
• Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO TrialNot yet recruitingNCT07297069Phase 2
• Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm StudyRecruitingNCT07295821Phase 2
• CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLRecruitingNCT07294677Phase 1/2
• PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric CancerRecruitingNCT07294664Phase 2
• A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)RecruitingNCT07294365Phase 2
• Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLCNot yet recruitingNCT07294261Phase 2
• Duvelisib Maintenance for the Treatment of Peripheral T-Cell LymphomasRecruitingNCT07293403Phase 2
• Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast CancerNot yet recruitingNCT07292207Phase 2
• Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01RecruitingNCT07290894Phase 2
• Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.Not yet recruitingNCT07289035Phase 2
• Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)RecruitingNCT07287202Phase 1/2
• A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingNCT07287150Phase 2
• Continuation Study of Zasocitinib in Adults With Psoriatic ArthritisRecruitingNCT07286058Phase 3
• Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell LymphomaRecruitingNCT07285590Phase 2
• A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung CancerNot yet recruitingNCT07285148Phase 1/2
• Amping up With PemJAKRecruitingNCT07283822Phase 2
• Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue SarcomaRecruitingNCT07283731Phase 2
• Pharmacokinetics of Olverembatinib in Participants With Hepatic ImpairmentRecruitingNCT07282093Phase 1
• Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based TreatmentRecruitingNCT07281833Phase 3
• Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren DiseaseRecruitingNCT07281456Phase 2
• Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic DiseaseRecruitingNCT07280702Phase 4
• Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumaticaRecruitingNCT07279688Phase 3
• Golidocitinib Combined With GemOx in RR PTCLNot yet recruitingNCT07279584Phase 2
• Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging SystemNot yet recruitingNCT07279532Phase 2
• Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell LymphomasRecruitingNCT07278856Phase 1
• A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaRecruitingNCT07277231Phase 3
• Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and AdultsNot yet recruitingNCT07276620Not applicable
• UDCA to Prevent Post-TIPS Hepatic EncephalopathyNot yet recruitingNCT07273734Not applicable
• Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and ForeheadNot yet recruitingNCT07273656Phase 3
• Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine NeoplasmsRecruitingNCT07272512Phase 4
• Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRecruitingNCT07272499Phase 2
• A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesRecruitingNCT07271667Phase 2
• Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric AdenocarcinomaRecruitingNCT07270991Phase 3
• Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaRecruitingNCT07270835Phase 4
• Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental SyndromeRecruitingNCT07270549Phase 1/2
• Senolytics for Secondary Progressive MSNot yet recruitingNCT07270120Phase 1

← Protein Kinase Inhibitors overview